| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System | ||
Topline Data Readout example | Phase 1/2 | — | Subscribe to access the data. | Gene Therapies | Nervous System |
Recent Updates
Recently added Catalysts
Taysha Gene Therapies, Inc.$5.59
+0.04 (+0.77%)
D 26Pipeline Score Richly Valued Biotech · Clinical
Market Cap
1.58 B
EPS
-0.40
P/E Ratio
-
Value Trade
9.15 M
SEC Financials
Q1 2026Dilution Risk
25%Revenue
-
R&D Expenses
33.81 M
Operating CF
-40.88 M
Total Assets
300.35 M
Total Liabilities
88.41 M
Equity
211.94 M
D/E Ratio
12,345
-10.88 %
Week
-13.68 %
1 Month
15.58 %
3 Month
37.59 %
6 Month
-75.03 %
5 Year
-75.33 %
All Time
Cash Data
Cash Position
276.58 M
Monthly Burn
13.63 M
Runway
17.6 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
81.64 K
52 Week Range
2.25 - 7.30
% held by Insiders
17.11 %
% held by Institutions
80.74 %
Enterprise Value
1.37 B
Total Shares
287.39 M
Short %
17.69 %
Float Shares
256.07 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Taysha Gene Therapies, Inc.
369Total events
7Upcoming
68Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 2
TBD
T3Manufacturing Milestone
Subscribe to view catalyst details
TBD
T2Runway Guidance Update
Subscribe to view catalyst details
Event history 2
TBD
◆Oral PresentationTSHA-102FiledPresentation
Subscribe to view catalyst details
TBD
▲Enrollment CompleteTSHA-102FiledTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-30 | TSHA-102 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-06-30 | TSHA-102 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
2026-06-30 | TSHA-102 | Pre-clinical data readout | Pre-clinical | — | – | – | – |
Drug Pipeline Intelligence
D26
Pipeline Score $0M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 27%
Micro Cap (rank 667 of 913)
Percentile RankTaysha Gene Therapies, Inc. faces pipeline headwinds (26/100), with 1 assets in development.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TSHA-101 Monoclonal antibody | Infantile GM2 Gangliosidosis (Disorder) | Phase 1 | NCT04798235 | 28% | $1M | ACTIVE NOT_RECRUITING | 3 | - | - | Mar 12, 2027 | VERY_HIGH_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TSHA-102 BreakthroughFast TrackRMAT+2 | Rett syndrome | Phase 1/2 | 2026-06-22 | 100% of REVEAL Part A patients (N=12,6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102; 310 total functional gains demonstrated ≥12 months post-TSHA-102 (~26 per patient); 31 developmental milestones and 279 additional skill gains/improvements Read More | Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome Read More | |
TSHA-102 BreakthroughFast TrackRMAT+2 | Rett syndrome | Phase 1/2 | 2026-06-22 | 100% of REVEAL Part A patients (N=12,6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102; 310 total functional gains demonstrated ≥12 months post-TSHA-102 (~26 per patient); 31 developmental milestones and 279 additional skill gains/improvements Read More | Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome Read More | |
TSHA-102 BreakthroughFast TrackRMAT+2 | Rett syndrome | Phase 1/2 | 2026-06-22 | 100% of REVEAL Part A patients (N=12,6-21 years) gained/regained ≥one developmental milestone by 12 months post-TSHA-102; 310 total functional gains demonstrated ≥12 months post-TSHA-102 (~26 per patient); 31 developmental milestones and 279 additional skill gains/improvements Read More | Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TSHA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TSHA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TSHATaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies has announced multiple presentations at the 2026 IRSF Rett Syndrome Scientific Meeting, showcasing the TSHA-102 clinical program. Recent data from the REVEAL Part A trial indicates significant functional improvements over time in patients. The company is advancing its investigational gene therapy aimed at addressing the genetic cause of Rett syndrome.
Read more →TSHA▼ -10.5%on this newsshared move
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The offering is intended to support the company's development of AAV-based gene therapies for severe CNS diseases. Jefferies, Goldman Sachs, Piper Sandler, and Cantor are managing the offering, which is subject to market conditions.
Read more →TSHATaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
Taysha Gene Therapies has completed dosing in the REVEAL pivotal trial for TSHA-102, a gene therapy for Rett syndrome. The interim analysis shows that all patients achieved developmental milestones within 12 months post-treatment, with significant functional gains. The company plans to engage with the FDA regarding a Biologics License Application (BLA) submission in early 2027, following positive longer-term data.
Read more →TSHA▼ -6.6%on this news
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies recently announced the granting of restricted stock units (RSUs) and stock options to four new employees as part of their induction process. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize staff retention and engagement. The RSUs totaling 714,700 shares and stock options for 468,600 shares underline the company's commitment to its new team members. Taysha continues to focus on developing gene therapies for severe monogenic diseases, enhancing its pipeline to address significant unmet medical needs.
Read more →TSHATaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies reported its Q1 2026 financial results, highlighting progress in its clinical development strategy for TSHA-102, a gene therapy for Rett syndrome. The company reaffirmed alignment with the FDA on its BLA submission pathway and advanced dosing in pivotal trials. Financially, Taysha reported a net loss of $42.4 million, reflecting increased R&D expenses. The company maintains a strong cash position to support its operations through 2028.
Read more →TSHATaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
Taysha Gene Therapies has granted restricted stock units (RSUs) to five new employees as part of its 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs, totaling 188,000 shares, will vest over four years, contingent on continued employment. Taysha focuses on AAV-based gene therapies for severe CNS diseases, including Rett syndrome.
Read more →TSHATaysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
Taysha Gene Therapies, Inc. will report its financial results for Q1 2026 on May 6. The company will host a conference call and webcast at 8:30 AM ET to provide a corporate update. Taysha focuses on AAV-based gene therapies for severe monogenic CNS diseases, with its lead program targeting Rett syndrome.
Read more →TSHATaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
Taysha Gene Therapies announced new preclinical data for TSHA-102, a gene therapy for Rett syndrome, showing that its self-complementary AAV9 construct significantly enhances MeCP2 protein expression. The data will be presented at the ASGCT Annual Meeting, supporting the ongoing Phase 1/2 REVEAL trials. The findings validate the construct design and highlight the potential for effective CNS delivery.
Read more →TSHATaysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on
Taysha Gene Therapies has reported significant advancements in its clinical trials for TSHA-102, an investigational gene therapy for Rett syndrome, with multiple patients dosed in the pivotal REVEAL trial and FDA clearance for the ASPIRE trial. The company continues to maintain a favorable tolerability profile and is on track to complete dosing by Q2 2026. Financially, however, Taysha reported a net loss of $109 million for 2025, primarily due to escalating research and administrative expenditures. The company remains optimistic about market demand and its registration path with the FDA.
Read more →TSHATaysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
Taysha Gene Therapies, Inc. announced it will report its full-year 2025 financial results on March 19, 2026. A conference call and webcast will be held at 8:30 AM Eastern Time. The company focuses on AAV-based gene therapies for severe CNS diseases, with a lead program for Rett syndrome.
Read more →TSHA▲ +7.6%on this news
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
Taysha Gene Therapies announced significant progress in the development of TSHA-102 for Rett syndrome, with the first patient dosed in the REVEAL pivotal trial. The company has also received alignment from the FDA on the inclusion of safety data from the ASPIRE trial in its planned Biologics License Application (BLA) submission. Completion of dosing for both trials is expected by Q2 2026. Taysha aims to address a substantial unmet medical need in a patient population of approximately 15,000 to 20,000 affected individuals.
Read more →TSHA▲ +7.9%on this news
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 5, 2025
Taysha Gene Therapies announced the grant of stock options to two new employees as part of its 2023 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The options, totaling 212,000 shares, have an exercise price of $4.49 and will vest over four years. Taysha focuses on AAV-based gene therapies for severe CNS diseases, with its lead program targeting Rett syndrome.
Read more →TSHATaysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Taysha Gene Therapies reported positive developments in its TSHA-102 program for Rett syndrome, including FDA Breakthrough Therapy designation and finalized trial protocols. The company is set to dose the first patient in its pivotal REVEAL trial in Q4 2025, with promising interim analysis results indicating a strong therapeutic potential. Taysha aims to address a significant unmet medical need for patients affected by Rett syndrome.
Read more →TSHATaysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) will report its financial results for the third quarter ended September 30, 2025, and host a corporate update conference call on November 4, 2025, at 8:30 AM Eastern Time. The company specializes in adeno-associated virus (AAV)-based gene therapies for severe central nervous system diseases. Its lead clinical program is focused on addressing Rett syndrome, a disorder with no current disease-modifying therapies. This indicates Taysha's commitment to meeting critical medical needs in the field of gene therapy.
Read more →TSHA▼ -7.1%on this news
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
Taysha Gene Therapies has regained full rights to its TSHA-102 program for Rett syndrome after the expiration of an option agreement with Astellas. The program has shown promising safety and efficacy data in clinical trials and has received FDA Breakthrough Therapy designation. The first patient dosing in the pivotal REVEAL trial is set for this quarter, marking a significant step towards potential registration.
Read more →TSHATaysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
Taysha Gene Therapies presented new data from the REVEAL Phase 1/2 trials for TSHA-102, showing a 100% response rate in patients with Rett syndrome. The supplemental analysis indicated additional functional gains beyond established developmental milestones. The findings emphasize the therapy's broad impact on daily living activities, supported by structured efficacy assessments.
Read more →TSHA▲ +53.5%on this newsshared move
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome Breakthrough Therapy designation granted based on FDA's review of available clinic
Taysha Gene Therapies has received FDA Breakthrough Therapy designation for TSHA-102, a gene therapy aimed at treating Rett syndrome. This designation follows a review of positive clinical evidence demonstrating a 100% response rate in the initial phase of their REVEAL trial. The FDA has also aligned with Taysha on the pivotal trial protocol, allowing them to proceed with plans for patient enrollment in the fourth quarter of 2025. TSHA-102 targets the genetic cause of Rett syndrome, which currently has no approved disease-modifying therapies.
Read more →TSHA▲ +5.4%on this news
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, followi
Taysha Gene Therapies has reported its financial results for the second quarter of 2025, highlighting significant progress in the development of TSHA-102 for Rett syndrome. The company commenced site activation for the pivotal REVEAL trial following regulatory endorsement, with patient enrollment expected to start in Q4 2025. Financially, Taysha raised $230 million through a public offering, bolstering its balance sheet to support ongoing operations through 2028. Despite a reported net loss of $26.9 million in Q2, the overall advancements in clinical trials present an optimistic outlook for the therapy's future.
Read more →TSHATaysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced the upcoming release of its financial results for the second quarter ending June 30, 2025. The company will host a conference call and webcast on August 12, 2025, at 8:30 AM Eastern Time to discuss these results. Taysha focuses on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, including its lead program for Rett syndrome, which lacks approved treatments. This update highlights Taysha's commitment to addressing critical medical needs in the field of gene therapy.
Read more →TSHATaysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program
Taysha Gene Therapies has announced the details for three oral presentations related to its TSHA-102 clinical program at the upcoming 2025 IRSF Rett Syndrome Scientific Meeting in Boston. The presentations will focus on recent updates, including clinical cohort data from Phase 1/2 trials and caregiver research on developmental milestones. TSHA-102 is designed as a one-time therapy targeting the genetic causes of Rett syndrome. The company expects these presentations to underscore the treatment's potential to meet the unmet needs of patients with this rare disease.
Read more →TSHA▲ +12.7%on this newsshared move
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Taysha Gene Therapies announced the pricing of its public offering, which includes 46.9 million shares of common stock priced at $2.75 each. Additionally, pre-funded warrants for 25.9 million shares are being offered at a price of $2.749 each. The offering is expected to close around May 30, 2025, and could yield the company roughly $200 million in gross proceeds. The company aims to advance gene therapies for severe CNS diseases, underscoring its commitment to addressing significant medical needs.
Read more →TSHA▼ -6.3%on this newsshared move
Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric T
Taysha Gene Therapies has unveiled the details of its pivotal Part B trial design for TSHA-102, aimed at treating Rett syndrome, following positive data from Part A of the REVEAL trials. This initiative is bolstered by natural history data from the International Rett Syndrome Foundation, which has established that developmental milestones are typically not regained after age six. Notably, 100% of participants in the previous trial reported gains in developmental milestones after treatment. The company plans to file the pivotal trial protocol as an amendment to its IND application within the current quarter, with trial initiation activities projected for Q3 2025.
Read more →TSHA▼ -6.3%on this newsshared move
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Dallas
Taysha Gene Therapies (TSHA) has announced a proposed underwritten public offering of common stock and pre-funded warrants to raise capital for its operations. This offering involves a 30-day option for underwriters to purchase an additional 15% of the shares. While this initiative aims to support the development of AAV-based gene therapies for severe monogenic diseases, it remains subject to market conditions, introducing uncertainty over its completion and specifics. The offering will follow a previously effective shelf registration statement filed with the SEC in December 2024.
Read more →TSHA▲ +8%on this news· ran to +24% by day 3
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling
Taysha Gene Therapies reported its first quarter 2025 financial results, highlighting regulatory advancements for its TSHA-102 gene therapy in the pivotal Part B trial for Rett syndrome. The company received FDA alignment on key trial elements, potentially expediting the study's initiation. Financially, R&D expenses decreased to $15.6 million, and Taysha maintains a strong cash position. Additional updates on trial design and clinical data are expected in the coming quarter, reflecting ongoing commitment to addressing urgent medical needs for Rett syndrome patients.
Read more →TSHA▲ +10.5%on this news· ran to +23% by day 3
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
Taysha Gene Therapies, a clinical-stage biotechnology company, announced that it will report its financial results for the first quarter of 2025 on May 15, 2025. The company is known for developing adeno-associated virus-based gene therapies for severe monogenic diseases of the central nervous system. The call will be held at 8:30 AM Eastern Time and includes a corporate update for stakeholders. Taysha's leading program focuses on potential treatments for Rett syndrome, underscoring its commitment to addressing rare disorders.
Read more →TSHATaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediat
Taysha Gene Therapies reported its full-year 2024 financial results and provided a corporate update, emphasizing the continued positive tolerance of its gene therapy product, TSHA-102, across various age groups. The company has completed dosing in Part A of its REVEAL trials and anticipates further updates on clinical data and a pivotal trial design in H1 2025. Financially, Taysha recorded a net loss of $89.3 million for 2024, which is a decrease compared to $111.6 million in the previous year, signaling improving fiscal health.
Read more →TSHATaysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26
Taysha Gene Therapies, Inc. has announced it will report its full-year financial results for 2024 and host a corporate update conference call on February 26, 2025. The company specializes in AAV-based gene therapies for severe monogenic diseases of the central nervous system, with a focus on Rett syndrome. Taysha aims to develop transformative medicines and improve patient outcomes, backed by a skilled management team in gene therapy. This announcement highlights the company's ongoing commitment to advancing its clinical programs and engaging with stakeholders.
Read more →TSHA▼ -7.5%on this news
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric pat
Taysha Gene Therapies has reported its third-quarter 2024 financial results and an update on its gene therapy TSHA-102 for Rett syndrome. The high-dose regimen showed a favorable safety profile, with no serious adverse events recorded in pediatric and adult patients. The FDA has approved the pivotal product for the ongoing REVEAL trials, which is expected to expedite its regulatory path. The company anticipates reporting more clinical data in the first half of 2025 as it continues discussions with the FDA regarding trial design and endpoints.
Read more →TSHA▲ +7.9%on this news· ran to +28% by day 3
Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
Taysha Gene Therapies announced it will release its financial results for Q3 2024 on November 13, 2024, at 4:30 PM ET. The company will also host a corporate update conference call and webcast. Taysha focuses on developing gene therapies for severe monogenic diseases of the central nervous system, with its lead program targeting Rett syndrome. This event will provide insights into the company's financial health and future directions.
Read more →TSHATaysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Taysha Gene Therapies, Inc. announced they will present biodistribution data from an analysis of AAV9 gene therapy delivery during the 31st Annual ESGCT Congress. The analysis, which involved five non-human primate studies, demonstrated effective lumbar IT and intra-cisterna magna administration methods for delivering the therapy to the central nervous system. These findings support Taysha's clinical development strategy for TSHA-102, targeted at treating Rett syndrome, a severe neurodevelopmental disorder with currently no disease-modifying therapies available.
Read more →TSHATaysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
Taysha Gene Therapies has announced an upcoming oral presentation on its TSHA-102 program for Rett syndrome at the 9th World Rett Syndrome Congress in Australia. The presentation will highlight previously disclosed positive clinical data from ongoing trials, with additional data expected to be reported in 2025. TSHA-102 is designed to address the genetic cause of Rett syndrome using a novel gene therapy approach. The company aims to provide valuable insights into the treatment's efficacy and potential impact on patient quality of life.
Read more →TSHATaysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update Presented cohort one (low dose) data from both trials of TSHA-102 at 2024 IRSF Rett Syndrome Scientific Meeting that demon
Taysha Gene Therapies reported promising results for TSHA-102 during its corporate update for Q2 2024, detailing durable improvements in clinical trials for Rett syndrome. The initial data indicated an encouraging safety profile, with no serious adverse events observed. Taysha's financial resources have been bolstered by a recent follow-on offering, extending its cash runway into 2026. Upcoming milestones include the dosing of additional patients in the pediatric and adolescent/adult trials.
Read more →TSHATaysha Gene Therapies to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 12
Taysha Gene Therapies, Inc. announced it will release its financial results for the second quarter of 2024 on August 12, 2024, at 8:30 AM Eastern Time. The company will also host a conference call and webcast to provide a corporate update. Taysha focuses on developing AAV-based gene therapies for severe monogenic diseases, with its lead program targeting Rett syndrome.
Read more →TSHA▼ -17.2%on this news
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants Dallas
Taysha Gene Therapies, a clinical-stage biotechnology firm, announced the pricing of a public offering of common stock and pre-funded warrants. The offering includes 14,361,113 shares priced at $2.25 each, expected to generate about $75 million in gross proceeds. The offering is set to close on or about June 27, 2024, pending regulatory conditions and includes a 30-day option for underwriters to purchase additional shares. Taysha is known for its focus on AAV-based gene therapies targeting severe neurological disorders.
Read more →TSHA▼ -26.3%on this news
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome Durable improvements across consiste
Taysha Gene Therapies has announced positive clinical data from the ongoing REVEAL Phase 1/2 trials for TSHA-102 in patients with Rett syndrome, showing durable improvements in motor skills, communication, and autonomic functions. The treatment demonstrated a favorable safety profile across both adult and pediatric cohorts, with initial data indicating developmental gains in young patients. The company received approval from the independent data monitoring committee to advance to a higher dose cohort in the pediatric trial, with further dosing expected in Q3 2024. This progress highlights the potential of TSHA-102 as a transformative therapy for individuals afflicted with this condition.
Read more →TSHATaysha Gene Therapies to Present Clinical Data from Both REVEAL Phase 1/2 Trials During Company-Hosted Webcast and at 2024 IRSF Rett Syndrome Scientific Meeting
Taysha Gene Therapies, Inc. announced a webcast on June 18, 2024, to present clinical data from their REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett syndrome. The data will also be presented at the 2024 IRSF Rett Syndrome Scientific Meeting. Key researchers, including Dr. Elsa Rossignol and Dr. Colleen Buhrfiend, will lead presentations on findings from their adolescent, adult, and pediatric studies. This event highlights Taysha's commitment to addressing severe monogenic diseases of the central nervous system through innovative gene therapies.
Read more →TSHA▲ +7.1%on this news· ran to +30% by day 1
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-te
Taysha Gene Therapies announced its financial results for Q1 2024, emphasizing progress in its clinical trials for TSHA-102, a gene therapy for Rett syndrome. The company completed dosing in the first cohort of the REVEAL trials and received Regenerative Medicine Advanced Therapy designation from the FDA, reinforcing the therapy's potential. Initial data from these trials is expected to provide insights into the therapy's safety and efficacy, with further developments scheduled for mid-2024 and later in the year. The company's financial overview indicates an increased net loss but sufficient cash reserves to support operations through 2026.
Read more →TSHA▼ -5.3%on this news
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced it will release its first quarter 2024 financial results on May 14 and will host a conference call and webcast. The call is scheduled for 4:30 PM Eastern Time. The company is focused on developing adeno-associated virus (AAV)-based gene therapies specifically for severe monogenic diseases of the central nervous system, including Rett syndrome. As a clinical-stage biotechnology company, Taysha aims to significantly improve patient outcomes.
Read more →TSHA▲ +6.6%on this newsshared move
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
Taysha Gene Therapies has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its investigational gene therapy TSHA-102, targeting Rett syndrome. This designation allows for expedited development and enhanced communication with regulatory authorities, enhancing the potential for quicker evaluation and approval. TSHA-102 aims to modify the genetic root cause of Rett syndrome by delivering a functional form of the MECP2 gene via AAV9 technology. Currently, no approved therapies exist that address this genetic condition, highlighting the significance of this development for affected patients.
Read more →TSHA▲ +5.6%on this news· ran to +53% by day 3
Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 (low dose, 5.7x10 14 total vg) was well-t
Taysha Gene Therapies reported full-year 2023 financial results and updates on its REVEAL Phase 1/2 trial for TSHA-102, a gene therapy for Rett syndrome. Notably, the therapy exhibited a well-tolerated profile in initial adult patients, with sustained clinical improvements observed in both subjects. The Independent Data Monitoring Committee approved early dose escalation and additional pediatric dosing. Financially, Taysha saw significant revenue growth and reduced net losses compared to the previous year, reflecting an evolving operational strategy.
Read more →TSHA▼ -5.3%on this newsshared move
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
Taysha Gene Therapies, Inc. has announced plans to release its full-year 2023 financial results on March 19, 2024, along with providing corporate and clinical updates. The event will include a conference call that stakeholders can join to gain insights into the company's progress, particularly in its lead program aimed at treating Rett syndrome. The conference call aims to address the company's strategies and advancements in developing gene therapies for severe monogenic diseases. Taysha continues to focus on developing transformative medicines for unmet medical needs.
Read more →TSHA▲ +19.7%on this newsshared move
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
Taysha Gene Therapies has announced significant updates to its TSHA-102 clinical program for treating Rett syndrome. The Independent Data Monitoring Committee has approved a dose escalation in the REVEAL Phase 1/2 adolescent and adult trial, enabling an earlier move to the high dose cohort. Additionally, the trial is expanding into the U.S. and is set to advance dosing in pediatric cohorts. Initial safety and efficacy data from the trials are anticipated in the coming months, potentially enhancing the treatment landscape for this rare disorder.
Read more →TSHA▲ +8.9%on this news· ran to +73% by day 3
Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
Taysha Gene Therapies provided an update on its deprioritized pipeline programs, which now receive new opportunities for advancement. The company has entered a new loan agreement, extending its cash runway to 2026, allowing for the efficient transfer of intellectual property to third parties. Significant developments include the initiation of clinical trial collaborations and the transfer of rights for various programs back to their originating institutions. Taysha continues to prioritize its lead program for Rett syndrome while seeking potential partnerships for its other deprioritized programs.
Read more →TSHATaysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
Taysha Gene Therapies, Inc. will present data on its gene therapy candidate TSHA-102 for Rett syndrome at the BPNA 2024 Annual Conference. The presentation will feature clinical data from the first two adult patients treated in the Phase 1/2 REVEAL trial. TSHA-102 employs a unique technology to modulate levels of the MECP2 gene, which is crucial for brain function. The therapy has gained Fast Track and Orphan Drug designations from the FDA, emphasizing its potential importance in a field with no existing disease-modifying treatments.
Read more →TSHA▼ -7.3%on this news· ran to -20% by day 3
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome Initiation of REVEAL pediatric trial in the U.S. broadens the clinical evaluation of TSHA-1
Taysha Gene Therapies has announced the dosing of its first pediatric patient with TSHA-102 in the REVEAL Phase 1/2 trial targeting Rett syndrome, specifically for female patients aged 5-8 years. This trial represents a significant extension of the company's clinical evaluation efforts into the pediatric demographic. The authorization of the Clinical Trial Application by the U.K.'s MHRA allows Taysha to expand the ongoing trial into the U.K. The company anticipates initial safety and efficacy data for the pediatric cohort to be available by mid-2024, building on positive findings from earlier trials in older populations.
Read more →TSHATaysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
Taysha Gene Therapies announced that Health Canada has authorized a protocol amendment to its REVEAL Phase 1/2 adult trial, now allowing inclusion of patients aged 12 and older with stage four Rett syndrome. This expansion aims to broaden the treatment potential of TSHA-102. The trial is currently ongoing, with the dosing of the third patient projected for late 2023 or early 2024. TSHA-102 is notable for its innovative gene therapy approach targeting the MECP2 mutation associated with Rett syndrome, a disorder primarily affecting females.
Read more →TSHATaysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-
Taysha Gene Therapies reported their third quarter 2023 financial results alongside updates on their REVEAL Phase 1/2 trial for TSHA-102, a gene therapy targeting Rett syndrome. Positive results from the trial suggest that TSHA-102 was well-tolerated, with early improvements noted in key clinical measures across two adult patients. Notably, the treatment showed sustained efficacy through the 12-week assessment. However, the company faced a substantial net loss this quarter mainly due to non-cash expenses, even as they secured financing that extends their cash runway into 2026.
Read more →TSHATaysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14
Taysha Gene Therapies, Inc. announced it will release its financial results for the third quarter ending September 30, 2023, on November 14, 2023. The company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide a corporate update. Taysha is dedicated to developing gene therapies for monogenic diseases affecting the central nervous system and collaborates with the UT Southwestern Gene Therapy Program.
Read more →TSHATaysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Taysha Gene Therapies presented promising preclinical in vitro data on TSHA-102 for Rett syndrome at the ESGCT 30th Annual Congress. The data highlights the miRARE regulation of MECP2 expression, demonstrating effective control over transgene levels in cell culture models. Upcoming clinical data from adult patients and the planned dosing of the first pediatric patient in early 2024 indicate continued advancements in their gene therapy approach. TSHA-102 has received several designations from regulatory agencies, underscoring its potential as a treatment option.
Read more →TSHA▼ -6%on this news
Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress
Taysha Gene Therapies has announced two poster presentations for its investigational gene therapy TSHA-102, aimed at treating Rett syndrome, during the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress. The presentations will showcase new preclinical in vitro data and initial clinical data from the first adult patient dosed in the REVEAL Phase 1/2 trial. The therapy employs a novel miRNA-Responsive Auto-Regulatory Element technology and has received Fast Track and Orphan Drug designations, underscoring its therapeutic potential in addressing an unmet medical need for this rare neurodevelopmental disorder.
Read more →TSHATaysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome Available clinical data from the two adult patients dosed with TSHA-102 in the fir
Taysha Gene Therapies has announced that the second patient has been dosed with TSHA-102 in the REVEAL Phase 1/2 adult trial for the treatment of Rett syndrome in Canada. The company anticipates completing enrollment in the low-dose cohort by the fourth quarter of 2023 and expects to dose the first pediatric patient in early 2024. The trial aims to evaluate the safety and preliminary efficacy of TSHA-102, a gene therapy targeting MECP2 mutations, with initial clinical data expected to be discussed during the upcoming earnings call in November.
Read more →TSHA▲ +5.2%on this news
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN) Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges wit
Taysha Gene Therapies has announced the discontinuation of its TSHA-120 program for treating giant axonal neuropathy (GAN) following feedback from the U.S. FDA regarding study design feasibility for Biologics License Application submission. The company is now pursuing external strategic options for TSHA-120 while focusing on the continued development of TSHA-102 for Rett syndrome, which is seen as a more viable path forward. This decision is anticipated to extend Taysha's cash runway into the fourth quarter of 2025.
Read more →TSHA▲ +5.4%on this news· ran to +52% by day 3
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with po
Taysha Gene Therapies has announced that the U.S. FDA granted Fast Track Designation for its gene therapy TSHA-102, designed to treat Rett syndrome. This designation aims to expedite the therapy's development and review process due to the significant unmet medical needs associated with the condition. TSHA-102 has also received other designations, including Orphan Drug status from the FDA and the European Union. Initial clinical results are promising, and the company plans to expand its trials to include pediatric patients soon.
Read more →TSHA▲ +188.2%on this news
Taysha Gene Therapies Announces $150 Million Private Placement Financing
Taysha Gene Therapies announced a private placement financing expected to yield $150 million in gross proceeds, aiming to extend its cash runway into Q3 2025. The financing is led by RA Capital Management and involves participation from several institutional investors. The funds are intended to support the clinical development of the company's treatments, primarily TSHA-102 for Rett syndrome and TSHA-120 for GAN. Taysha also plans to file a registration statement for the resale of the offered shares.
Read more →TSHA▲ +188.2%on this news
Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results Data from first adult pa
Taysha Gene Therapies has announced initial clinical data from the REVEAL Phase 1/2 trial, reporting that the first adult patient treated with TSHA-102 for Rett syndrome experienced significant clinical improvements and a well-tolerated safety profile. The company has also received FDA clearance to explore TSHA-102 in pediatric patients and secured $150 million in private placement financing to extend its operational runway into 2025. The ongoing evaluation aims to assess the therapy's impact on a larger scale despite the small initial cohort.
Read more →TSHATaysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial conti
Taysha Gene Therapies has received a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the REVEAL Phase 1/2 trial of its gene therapy TSHA-102 for Rett syndrome. The IDMC's recommendation was based on encouraging initial clinical data from the first adult patient dosed with TSHA-102. Dosing of a second patient is expected to commence in the third quarter of 2023, which reflects the ongoing commitment to developing treatments for this rare genetic disorder. Initial clinical updates will be provided during the company's second quarter corporate update conference call in mid-August.
Read more →TSHATaysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day Company views that results of comprehensive data analysis of
Taysha Gene Therapies has provided updates on its clinical programs TSHA-120 for Giant Axonal Neuropathy (GAN) and TSHA-102 for Rett syndrome. Comprehensive analyses suggest a potential regulatory path for TSHA-120, addressing prior FDA concerns. In addition, initial positive observations were noted for the first adult patient treated with TSHA-102 in its ongoing REVEAL Phase 1/2 trial. Further updates, including a formal meeting with the FDA concerning TSHA-120, are anticipated in Q3 2023.
Read more →TSHATaysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome
Taysha Gene Therapies is scheduled to host a virtual R&D Day on June 28, 2023, to present updates on its clinical programs for TSHA-120 in Giant Axonal Neuropathy and TSHA-102 in Rett Syndrome. The event will feature insights from collaborator Dr. Salman Bhai, who will discuss GAN and share new data from ongoing trials. Initial safety observations for TSHA-102 will also be shared, with more detailed updates expected in the third quarter following an independent data review.
Read more →TSHA▲ +5.1%on this news
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome The Phase 1/2 REVEAL trial is a first-in-human, randomized, dose-esca
Taysha Gene Therapies has dosed the first patient with TSHA-102 in its Phase 1/2 REVEAL trial aimed at treating Rett syndrome, marking a groundbreaking advancement in gene therapy. This study is the first of its kind to evaluate a gene therapy for Rett syndrome and utilizes innovative miRARE technology to regulate MECP2 expression. Initial safety data will be presented at an upcoming R&D Day on June 28, 2023. If successful, TSHA-102 could address the unmet needs of patients living with this challenging condition.
Read more →TSHA▲ +5.6%on this news
Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26 th Annual Meetin
Taysha Gene Therapies presented promising preclinical data at the ASGCT 26th Annual Meeting regarding TSHA-102 for Rett syndrome. This gene therapy utilizes innovative miRARE technology to regulate MeCP2 expression in neonatal mouse models. The results indicate effective regulation of MeCP2 levels without adverse effects on health in wild-type mice. These findings support the ongoing Phase 1/2 REVEAL trial, where dosing of adult patients is anticipated.
Read more →TSHA▼ -5.5%on this news
Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update Screening completed and dosing scheduled for first potential subject in the Phase 1/2 REVEAL trial in Rett syndrome; dosing
Taysha Gene Therapies has reported its financial results for the first quarter of 2023, showcasing advancements in its clinical programs, particularly TSHA-102 for Rett syndrome. The company has completed screening for the Phase 1/2 REVEAL trial, with dosing for the first patient scheduled. Additionally, Taysha plans to submit a Clinical Trial Application in the UK and an Investigational New Drug application in the US later this year. Financially, the company has reduced its losses significantly compared to the previous year, underscoring improved expense management while maintaining a focus on regulatory submissions and data presentations.
Read more →TSHA▲ +5.2%on this news
Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11
Taysha Gene Therapies, a clinical-stage gene therapy company, announced it will release its financial results for the first quarter of 2023 on May 11. Alongside the results, the company will host a conference call and webcast to provide a corporate update. With a focus on developing gene therapies for monogenic diseases of the central nervous system, Taysha aims to improve patient outcomes through its innovative treatments.
Read more →TSHATaysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting
Taysha Gene Therapies announced that it will present new preclinical data for its TSHA-102 program at the American Society of Gene and Cell Therapy's 26th Annual Meeting. The presentation will focus on a study showing improvements in survival, weight, and behavior in a mouse model of Rett syndrome. TSHA-102 is an AAV9 gene transfer therapy currently under evaluation for this rare neurodevelopmental disorder. This presentation may enhance Taysha's visibility within the gene therapy field.
Read more →TSHA▼ -6.2%on this news
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Initiated screening of first potential subject in Phase 1/2 REVEAL trial in Rett syndrome; dosing of first a
Taysha Gene Therapies has reported its fourth quarter and full-year 2022 financial results while providing an update on its clinical programs. The company has initiated screening for its Phase 1/2 REVEAL trial in Rett syndrome and anticipates dosing the first patient in H1 2023. Additionally, they plan to submit a Clinical Trial Application to the UK in mid-2023 and an Investigational New Drug application to the FDA for Rett syndrome in H2 2023. However, Taysha experienced a net loss of $55.7 million in Q4 2022, alongside significant impairment charges.
Read more →TSHATaysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
Taysha Gene Therapies, Inc. announced it will report its financial results for Q4 and full-year 2022 on March 28, 2023. The announcement includes a conference call and webcast to discuss the results at 4:30 PM Eastern Time. The company focuses on developing AAV-based gene therapies for monogenic rare diseases affecting the central nervous system, aiming for rapid translation from research to clinical application.
Read more →TSHA▲ +6.5%on this news· ran to -21% by day 1
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for
Taysha Gene Therapies has provided a corporate update regarding the TSHA-120 program for giant axonal neuropathy, highlighting productive engagement with the FDA. The FDA has accepted MFM32 as a valid endpoint and recommended additional patient dosing in a controlled trial to support BLA submission. Additionally, the company plans to submit a Clinical Trial Application for TSHA-102 aimed at treating pediatric Rett syndrome. Strategic organizational changes have also been made to improve operations and milestone execution in 2023.
Read more →TSHA▼ -7%on this news
Taysha Gene Therapies Announces Executive Leadership Changes Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of R&D
Taysha Gene Therapies Announces Executive Leadership Changes Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of R&D Dallas December 16, 2022 - Taysha Gene Therapies, Inc. (N
Read more →TSHATaysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHA▲ +10%on this news
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update $50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) a
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update $50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome Proceeds from follow-on offe
Read more →TSHATaysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHA▼ -27.5%on this news· ran to -43% by day 1
Taysha Announces Pricing of Public Offering of Common Stock Dallas
Taysha Announces Pricing of Public Offering of Common Stock Dallas October 26, 2022 (GLOBE NEWSWIRE) Taysha Gene Therapies, Inc. (Nasdaq: TSHA) ( Taysha ), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies f
Read more →TSHA▲ +97.4%on this newsshared move
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock Dallas
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock Dallas October 25, 2022 - Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatm
Read more →TSHAAstellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha s AAV-based Gene Therapy Programs - Taysha Gene Therapies is an emerging leader in the development of AAV ge
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha s AAV-based Gene Therapy Programs - Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two
Read more →TSHATaysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs
DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHATaysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHA▼ -19.1%on this news
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential
Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natura
Read more →TSHA▲ +5.2%on this newsshared move
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHATaysha Gene Therapies to Participate in Upcoming August Investor Conferences
BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy
Read more →TSHA▲ +8.5%on this news
Taysha Gene Therapies to Participate in Upcoming William Blair Biotech Focus Conference 2022
DALLAS, July 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHA▼ -17.2%on this news
Taysha Gene Therapies Announces Annual Stockholder Meeting
DALLAS, June 13, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CN
Read more →TSHATaysha Gene Therapies to Participate in Upcoming June Investor Conferences and Convention
Jefferies Healthcare Conference on June 8, 2022 at 9:30 am ET Goldman Sachs 43rd Annual Global Healthcare Conference on June 14, 2022 at 11:20 am PT BIO International Convention on June 15, 2022 at 11:00 am PT JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 pm
Read more →TSHATaysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with
Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022 Drug
Read more →TSHA▼ -14.5%on this newsshared move
Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16
DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS
Read more →TSHATaysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy
DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS
Read more →TSHA▲ +8.9%on this news
Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)
Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to estimated natural history decline of 24 points Biopsy data in five of six patie
Read more →TSHATaysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit
DALLAS, April 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (C
Read more →TSHA▼ -7.4%on this news
Taysha Gene Therapies to Participate in Upcoming Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
Chief Executive Officer, Chief Technical Officer, Chief Medical Officer and Head of Research and Development and Senior Vice President of Manufacturing to participate in a panel discussion at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on April 25, 2022 at
Read more →TSHA▲ +6%on this news
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Strategic pipeline prioritization initiatives focused on giant axonal neuropathy (GAN), with feedback on reg
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Strategic pipeline prioritization initiatives focused on giant axonal neuropathy (GAN), with feedback on registration pathway by mid-2022, and Rett syndrome, with preliminar
Read more →TSHA▲ +10.7%on this news
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy Efficacy data for high dose cohort demonstrated clinical
Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy Efficacy data for high dose cohort demonstrated clinically meaningful and statistically significant improvement i
Read more →TSHA▼ -10.8%on this newsshared move
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of -Hexosaminidase A Enzyme Activity in Patients with
Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of -Hexosaminidase A Enzyme Activity in Patients with GM2 Gangliosidosis Patient 1 with Sandhoff disease realize
Read more →TSHA▲ +5.1%on this news
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x10 14 total vg in GAN
Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update Anticipate clinical safety and MFM32 functional data for TSHA-120 from the highest dose cohort of 3.5x1014 total vg in GAN in December 2021 Expect preliminary clinical safety data
Read more →TSHATaysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a
Taysha Announces Exclusive Option from UTSW to License Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program for CLN7 Disease, a Research Collaboration with UTSW to Develop Next-Generation Construct for CLN7 and a Grant Award to Batten Hope currently in Phase 1 clinical
Read more →TSHA▼ -9%on this news
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update Positive pre-IND/CTA feedback obtained from several key regulatory agencies for TSHA-102 in Rett syndrome, TSHA-101 in GM2
Taysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update Positive pre-IND/CTA feedback obtained from several key regulatory agencies for TSHA-102 in Rett syndrome, TSHA-101 in GM2 gangliosidosis and TSHA-118 in CLN1 disease, paving the wa
Read more →TSHALegal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in
RESEARCH & DEVELOPMENT DAY DAY 2 - June 29, 2021 | 9:00 AM - 12:00 PM CT Bringing New Cures to Life Exhibit 99.1 Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements,
Read more →TSHATaysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update TSHA-120 program demonstrated clear arrest of disease progression and long-term durability at therapeutic dose levels in
Taysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update TSHA-120 program demonstrated clear arrest of disease progression and long-term durability at therapeutic dose levels in patients with giant axonal neuropathy (GAN); Expects clini
Read more →TSHABringing New Cures to Life Corporate Presentation April 2021 Legal Disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All stateme
Legal Disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strat
Read more →TSHATaysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease Prog
Taysha Gene Therapies Acquires Exclusive Worldwide Rights to Clinical-Stage AAV9 Gene Therapy Program, Now Known as TSHA-120, for the Treatment of Giant Axonal Neuropathy, a Rare and Severe Neurodegenerative Disease Program invented in the lab of Dr. Steven Gray, Taysha s Chie
Read more →TSHATaysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders Taysha to have an exclusive option on new payloads, co
Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research
Read more →TSHATaysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update Successfully raised $96 million in Series B financing and completed $181 million IPO Established management team with succes
Taysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update Successfully raised $96 million in Series B financing and completed $181 million IPO Established management team with successful track record of developing and commercializing AAV9-
Read more →TSHATaysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update Expects preliminary Phase 1/2 safety and biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis from the
Taysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update Expects preliminary Phase 1/2 safety and biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis from the Queen s University study in second half of 2021 and by yea
Read more →TSHATaysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders Collaboration with Cleveland Clinic
Taysha Gene Therapies Announces Collaborations to Advance Next-Generation Mini-Gene Payloads for AAV Gene Therapies for the Treatment of Genetic Epilepsies and Additional CNS Disorders Collaboration with Cleveland Clinic to support creation of novel next-generation mini-gene p
Read more →TSHATaysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook Expects Phase 1/2 biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis in second half of 2021 and by year-end
Taysha Gene Therapies Highlights Strategic Priorities and Provides 2021 Business Outlook Expects Phase 1/2 biomarker and preliminary clinical data for TSHA-101 in GM2 gangliosidosis in half of 2021 and by year-end 2021, respectively Plans to initiate a U.S. Phase 1/2 trial for
Read more →TSHATaysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency Designations reinforce unmet need for treatment options for patie
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-105 for the Treatment of Epilepsy Caused by SLC13A5 Deficiency Designations reinforce unmet need for treatment options for patients with rare form of genetic epilepsy second program fro
Read more →TSHATaysha Gene Therapies Announces Queen s University s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis TSHA-101 t
Taysha Gene Therapies Announces Queen s University s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis TSHA-101 to be first bicistronic vector evaluated in human clinical
Read more →TSHATaysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility Approximately 187,000 square foot facility located in Durham, NC designed to support preclinical through commercial cGMP manufacturing for Tays
Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility Approximately 187,000 square foot facility located in Durham, NC designed to support preclinical through commercial cGMP manufacturing for Taysha s broad pipeline of gene therapies Multiple production
Read more →TSHATaysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 for the Treatment of Epilepsy Caused by SLC6A1 Haploinsufficiency Designations provide validation of encouraging preclinical
Taysha Gene Therapies Receives Rare Pediatric Disease and Orphan Drug Designations for TSHA-103 for the Treatment of Epilepsy Caused by SLC6A1 Haploinsufficiency Designations provide validation of encouraging preclinical data generated to date TSHA-103 joins portfolio of rare
Read more →TSHATaysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeut
Taysha Gene Therapies Adds Industry-Leading Gene Therapy Executives to Board of Directors Appoints former Chief Medical Officer of Spark Therapeutics, Kathy Reape, M.D., and Chief Scientific Officer of Intellia Therapeutics, Laura Sepp-Lorenzino, Ph.D., to board of directors D
Read more →TSHATaysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership with Catalent Partnership to support Taysha s broad gene therapy pipeline Development and manufacturing partnership will support future preclinica
Taysha Gene Therapies Bolsters Manufacturing Capacity Through Partnership Partnership to support Taysha s broad gene therapy pipeline Development and manufacturing partnership will support future preclinical and clinical supply for several gene therapy programs, including CLN1
Read more →TSHATaysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-104 to Treat SURF1-Associated Leigh Syndrome Taysha anticipated to submit Investigational New Drug Application for TS
Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-104 to Treat SURF1-Associated Leigh Syndrome Taysha anticipated to submit Investigational New Drug Application for TSHA-104 to FDA in 2021 Rare pediatric disease and orphan
Read more →TSHATaysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome Program leverages novel miRARE platform technology used to control transgene exp
Taysha Gene Therapies Receives Rare Pediatric Disease Designation and Orphan Drug Designation for TSHA-102 as a Treatment for Rett Syndrome Program leverages novel miRARE platform technology used to control transgene expression on a cellular basis TSHA-102 anticipated to submi
Read more →TSHATaysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications Detect Lysosomal Storage Disorders program re
Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications Detect Lysosomal Storage Disorders program reduces barriers to genetic diagnosis through sponsored tes
Read more →Competitive Position
How TSHA ranks across every disease it competes inCompetitive Position is a premium feature
See how TSHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial